NCT02712346View on ClinicalTrials.gov

The Role of Endothelin-1 in Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 30, 2019

Study Completion Date

November 30, 2019

Conditions

Sickle Cell Anemia

Interventions

DRUG

Ambrisentan

Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks

DRUG

Placebo

One inactive pill daily for twelve weeks

Trial Locations (1)

30912

Augusta University, Augusta

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Augusta University

OTHER